8 ms·

451: Unavailable due to legal reasons We recognize you are attempting to access this website from a country belonging to the European Economic Area (EEA) inclu

by Spixel 7y ago

451: Unavailable due to legal reasons We recognize you are attempting to access this website from a country belonging to the European Economic Area (EEA) including the EU which enforces the General Data Protection Regulation (GDPR) and therefore access cannot be granted at this time. For any issues, contact web@tulsaworld.com or call 918-581-8300.

citruspi 7y ago
https://pastebin.com/jvqcradG https://pastebin.com/jvqcradG
kahseng 7y ago
If helpful, here's what the US sees https://ctxt.io/2/AACAZ3Z6FA https://ctxt.io/2/AACAZ3Z6FA
mcuelenaere 7y ago
https://web.archive.org/web/20190720170128/https://www.tulsaworld.com/news/after-edmond-man-says-dog-dewormer-cured-his-cancer-researchers/article_00691b72-a223-51a5-aec0-e743faf1eed4.html https://web.archive.org/web/20190720170128/https://www.tulsa...
xenospn 7y ago
After an Edmond man claimed a dewormer medication meant for dogs cured him of small-cell lung cancer, some cancer researchers now want to learn more about the mysterious drug that is piquing patient interest. Joe Tippens was only given three months to live. But doctors later enrolled him in a clinical trial they hoped could give him more time. Tippens said he received a tip from a veterinarian who suggested he try a dog dewormer drug called fenbendazole, which was believed to display cancer-fighting properties, according to cell studies. In his blog, Tippens wrote that after receiving his fourth cancer-free diagnosis at the University of Texas MD Anderson Cancer Center in Houston last April, the results indicated that his cancer was gone after two years of treatment. Dr. Stephen Prescott, Oklahoma Medical Research Foundation president, said Tippens’ story interested him after speaking to a scientist at Johns Hopkins University who conducted a case study where scientists implanted immune-deficient mice with human tumors. While the experiment was still in progress, a veterinarian at Johns Hopkins University put the mice on the same deworming medications that Tippens used. After examining the results, scientists found that the implanted tumors would not grow, he said. “They were trying to make cancer in mice and unbeknownst to them, something that the veterinarian in the facility had done prevented that,” Prescott said. Shortly after, Prescott said he met Tippens through mutual friends. While director of the Huntsman Cancer Institute in Salt Lake City, Prescott said he “would hear stories all the time about new approaches to cancer medical treatments,” but remained skeptical. However, Prescott said he and a team Tippens is putting together will collaborate to explore alternative care methods. “It would be a wonderful thing if we discovered that there is this compound that has broad activity with dramatic responses like with Mr. Tippens, what a great thing that would be,” he said. Prescott said they plan to spend six to 12 months researching the medical records of cancer patients. In their study, they will consider specifics such as the treatment they received, how they reacted and how long they were given to live. By studying Tippens’ case further, Prescott said they could provide more truth to the dog dewormer medicinal impact. One problem made evident by some anticancer medications is that over time they become ineffective, he said. It is the reason why patients today are seeking other treatments. Most anticancer drugs attack a specific target on or in the cancer cell, he explained. “What often happens is that it works initially and then quits working,” Prescott said. “And the reason is the cancer has continued to change and have additional mutations, so what was the initial targets no longer respond to the drug.” Part of Tippens’ treatment regimen was CBD. Chip Paul, the founder of Owasso-based GnuPharma, a company that specializes in developing natural products, said he is unsure how influential CBD alone was on Tippens’ cancer cells. “If he was just taking cannabidiol, it is doubtful that it affected his cancer because it does not have the right actives in it to be able to signal that,” Paul said. Prescott said as the clinical trial develops, he hopes that it will eventually lead to answers regarding Tippens’ shocking recovery. “I do really applaud Mr. Tippens for his forthrightness and aggressive stance for something he believes has helped him and can help us as a people,” Prescott said. “He has done more than any patient has done in that regard.”
ylere 7y ago
https://outline.com/V2UVYc https://outline.com/V2UVYc
rootsudo 7y ago
The tongue in cheek is really good at 451.
guggle 7y ago
Joe Tippens was only given three months to live. But doctors later enrolled him in a clinical trial they hoped could give him more time. Tippens said he received a tip from a veterinarian who suggested he try a dog dewormer drug called fenbendazole, which was believed to display cancer-fighting properties, according to cell studies. In his blog, Tippens wrote that after receiving his fourth cancer-free diagnosis at the University of Texas MD Anderson Cancer Center in Houston last April, the results indicated that his cancer was gone after two years of treatment. Dr. Stephen Prescott, Oklahoma Medical Research Foundation president, said Tippens’ story interested him after speaking to a scientist at Johns Hopkins University who conducted a case study where scientists implanted immune-deficient mice with human tumors. While the experiment was still in progress, a veterinarian at Johns Hopkins University put the mice on the same deworming medications that Tippens used. After examining the results, scientists found that the implanted tumors would not grow, he said. “They were trying to make cancer in mice and unbeknownst to them, something that the veterinarian in the facility had done prevented that,” Prescott said. Shortly after, Prescott said he met Tippens through mutual friends. While director of the Huntsman Cancer Institute in Salt Lake City, Prescott said he “would hear stories all the time about new approaches to cancer medical treatments,” but remained skeptical. However, Prescott said he and a team Tippens is putting together will collaborate to explore alternative care methods. “It would be a wonderful thing if we discovered that there is this compound that has broad activity with dramatic responses like with Mr. Tippens, what a great thing that would be,” he said. Prescott said they plan to spend six to 12 months researching the medical records of cancer patients. In their study, they will consider specifics such as the treatment they received, how they reacted and how long they were given to live. By studying Tippens’ case further, Prescott said they could provide more truth to the dog dewormer medicinal impact. One problem made evident by some anticancer medications is that over time they become ineffective, he said. It is the reason why patients today are seeking other treatments. Most anticancer drugs attack a specific target on or in the cancer cell, he explained. “What often happens is that it works initially and then quits working,” Prescott said. “And the reason is the cancer has continued to change and have additional mutations, so what was the initial targets no longer respond to the drug.” Part of Tippens’ treatment regimen was CBD. Chip Paul, the founder of Owasso-based GnuPharma, a company that specializes in developing natural products, said he is unsure how influential CBD alone was on Tippens’ cancer cells. “If he was just taking cannabidiol, it is doubtful that it affected his cancer because it does not have the right actives in it to be able to signal that,” Paul said. Prescott said as the clinical trial develops, he hopes that it will eventually lead to answers regarding Tippens’ shocking recovery. “I do really applaud Mr. Tippens for his forthrightness and aggressive stance for something he believes has helped him and can help us as a people,” Prescott said. “He has done more than any patient has done in that regard.”
hanniabu 7y ago
Click the "web" link below the link to the story and select another source
echelon 7y ago
This is one of the many viable options US companies have for dealing with EU traffic. GDPR compliance can be extremely expensive to implement, especially for complex software comprised of thousands of microservices that handle customer data. And imagine working in an industry where data retention is legally mandated by other jurisdictions... I'm not saying GDPR is bad (I'm all in favor!), but the costs can be quite large to implement to the letter of the law (GDPR export requirements, etc)
- rlpb 7y ago
  > GDPR compliance can be extremely expensive to implement... Bullshit. It's trivial to implement. Don't store my personal data. Done. It may be extremely expensive to store and process my personal data and remain GDPR compliant, if you insist on doing that. And admittedly it may be expensive to store and process others' personal data while excluding EU citizens from that mechanism. But the blanket statement "GDPR compliance can be extremely expensive to implement" is on its own extremely misleading in this context. > And imagine working in an industry where data retention is legally mandated by other jurisdictions... Perhaps, but this is not relevant to a news organisation publishing a general article online from the USA, where (AFAIK) there is no such data retention requirement in any jurisdiction within the USA.
  - sagebird 7y ago
    It is not trivial for publishers who have years of adding advertising and analytics tools to their website to come up with a strategy for peeling these back or checking compliance. If I had a blog, it would be easy for me to check and decide what to remove or modify. But being part of an organization means that most of the shit on a publisher’s network is a manager’s baby project and is going to require meetings, ego stroking, and if you suggest a change then revenue drops, you will be prime suspect. Not to mention months of managers saying — “well we used to have this really great analytics platform that helped me steer this company but now I can’t do my job because so and so deactivated X”. For many of the tools you might have a contract with a company to provide service. They have people specifically hired to be persuasive calling your leadership to try to keep the relationship going, so they will fight to keep you as a customer. I think the interesting thing is that you can’t pass the buck, you are ultimately responsible for providing compliance, not just choosing tools that claim compliance.
bryanrasmussen 7y ago
As I was trying to find a non gdpr resistant news article I happened to come across this https://www.thesun.co.uk/news/9344028/cocaine-rot-skin-genitals-drug-cut-cattle-dewormer/ https://www.thesun.co.uk/news/9344028/cocaine-rot-skin-genit... "COKE ROT Cocaine can ROT your skin and genitals – as drug is cut with dangerous cattle de-wormer, experts warn" the interesting thing is in the article it says cocaine can be cut with Levamisole, which: was used to treat arthritis and bowel cancer in the past, but it was banned for use by humans in 2000....Now, it's only supposed to be used in veterinary medicine to kill parasitic worms.
- cwkoss 7y ago
  I wonder if cocaine users have lower incidences of certain kinds of cancers? Would be an interesting thing to look for in large epidemiological studies.
Chris_Chambers 7y ago
How can countries even be accurately detected? IP lookup table? Blindly guessing based on the Accept-Language header?
tass 7y ago
Does this kind of action actually absolve them of GDPR responsibilities? If an EU citizen/resident/etc accessed the site from a country that’s not blocked, or via VPN, are they unable to ask for their information or have it scrubbed? What if a person later becomes an EU citizen? What if they are a dual citizen? I don’t understand how these geo blockers are able to make anyone compliant.
- cheald 7y ago
  > Does this kind of action actually absolve them of GDPR responsibilities? All the rest of our laws travel with jurisdictions, not with individuals' citizenship status. The GDPR doesn't really have any standing to impose obligations on companies that refuse to do business inside EU jurisdictions. We won't know until it's tested in court, but demonstrating a best effort to keep your product out of EU jurisdiction seems like a pretty good first defense.
  - ivolimmen 7y ago
    But if a EU citizen has an account already they are bound to the GDPR. Blocking this account only makes it worse (legally).
    - cheald 7y ago
      The GDPR might assert that they're bound, but an Oklahoma-based business with no business presence or assets inside the EU isn't bound by EU law. This is pretty much the foundation of national sovereignty. How would an EU enforcer actually enforce the GDPR in this case? Unless there's been a violation of a trade agreement, any attempt to apply EU law to a US-based company operating on US soil is going to be utterly impotent.
      - mattlondon 7y ago
        No any company that deals with people in the EU (even non-EU citizens physically in the EU) needs to obey GDPR - simple site explaining it simply here: https://www.compliancejunction.com/countries-subject-gdpr-privacy-law/ https://www.compliancejunction.com/countries-subject-gdpr-pr... Geo location for IPs is a very inexact science so they almost certainly are processing EU citizens' data. Hell I can access it with a VPN while sat in the EU so yep, they are liable if they store anything about me (apparently IP addresses are considered PII in terms of GDPR too) No idea how they'd enforce it - various murky-references to "international law" are floating around. I guess these sort of things are covered in trade treaties etc like with patents and copyright etc.
hrbf 7y ago
I'm pretty sure this is a wrong use of the spirit of HTTP code 451. It is meant for censorship by external forces like governments. If you block people from legislations that don’t allow invasive tracking by default, it’s you doing the censorship, for economic gain no less.

by Spixel 7y ago

citruspi 7y ago

https://pastebin.com/jvqcradG https://pastebin.com/jvqcradG

kahseng 7y ago

If helpful, here's what the US sees https://ctxt.io/2/AACAZ3Z6FA https://ctxt.io/2/AACAZ3Z6FA

mcuelenaere 7y ago

https://web.archive.org/web/20190720170128/https://www.tulsaworld.com/news/after-edmond-man-says-dog-dewormer-cured-his-cancer-researchers/article_00691b72-a223-51a5-aec0-e743faf1eed4.html https://web.archive.org/web/20190720170128/https://www.tulsa...

xenospn 7y ago

After an Edmond man claimed a dewormer medication meant for dogs cured him of small-cell lung cancer, some cancer researchers now want to learn more about the mysterious drug that is piquing patient interest. Joe Tippens was only given three months to live. But doctors later enrolled him in a clinical trial they hoped could give him more time. Tippens said he received a tip from a veterinarian who suggested he try a dog dewormer drug called fenbendazole, which was believed to display cancer-fighting properties, according to cell studies. In his blog, Tippens wrote that after receiving his fourth cancer-free diagnosis at the University of Texas MD Anderson Cancer Center in Houston last April, the results indicated that his cancer was gone after two years of treatment. Dr. Stephen Prescott, Oklahoma Medical Research Foundation president, said Tippens’ story interested him after speaking to a scientist at Johns Hopkins University who conducted a case study where scientists implanted immune-deficient mice with human tumors. While the experiment was still in progress, a veterinarian at Johns Hopkins University put the mice on the same deworming medications that Tippens used. After examining the results, scientists found that the implanted tumors would not grow, he said. “They were trying to make cancer in mice and unbeknownst to them, something that the veterinarian in the facility had done prevented that,” Prescott said. Shortly after, Prescott said he met Tippens through mutual friends. While director of the Huntsman Cancer Institute in Salt Lake City, Prescott said he “would hear stories all the time about new approaches to cancer medical treatments,” but remained skeptical. However, Prescott said he and a team Tippens is putting together will collaborate to explore alternative care methods. “It would be a wonderful thing if we discovered that there is this compound that has broad activity with dramatic responses like with Mr. Tippens, what a great thing that would be,” he said. Prescott said they plan to spend six to 12 months researching the medical records of cancer patients. In their study, they will consider specifics such as the treatment they received, how they reacted and how long they were given to live. By studying Tippens’ case further, Prescott said they could provide more truth to the dog dewormer medicinal impact. One problem made evident by some anticancer medications is that over time they become ineffective, he said. It is the reason why patients today are seeking other treatments. Most anticancer drugs attack a specific target on or in the cancer cell, he explained. “What often happens is that it works initially and then quits working,” Prescott said. “And the reason is the cancer has continued to change and have additional mutations, so what was the initial targets no longer respond to the drug.” Part of Tippens’ treatment regimen was CBD. Chip Paul, the founder of Owasso-based GnuPharma, a company that specializes in developing natural products, said he is unsure how influential CBD alone was on Tippens’ cancer cells. “If he was just taking cannabidiol, it is doubtful that it affected his cancer because it does not have the right actives in it to be able to signal that,” Paul said. Prescott said as the clinical trial develops, he hopes that it will eventually lead to answers regarding Tippens’ shocking recovery. “I do really applaud Mr. Tippens for his forthrightness and aggressive stance for something he believes has helped him and can help us as a people,” Prescott said. “He has done more than any patient has done in that regard.”

ylere 7y ago

https://outline.com/V2UVYc https://outline.com/V2UVYc

rootsudo 7y ago

The tongue in cheek is really good at 451.

guggle 7y ago

Joe Tippens was only given three months to live. But doctors later enrolled him in a clinical trial they hoped could give him more time. Tippens said he received a tip from a veterinarian who suggested he try a dog dewormer drug called fenbendazole, which was believed to display cancer-fighting properties, according to cell studies. In his blog, Tippens wrote that after receiving his fourth cancer-free diagnosis at the University of Texas MD Anderson Cancer Center in Houston last April, the results indicated that his cancer was gone after two years of treatment. Dr. Stephen Prescott, Oklahoma Medical Research Foundation president, said Tippens’ story interested him after speaking to a scientist at Johns Hopkins University who conducted a case study where scientists implanted immune-deficient mice with human tumors. While the experiment was still in progress, a veterinarian at Johns Hopkins University put the mice on the same deworming medications that Tippens used. After examining the results, scientists found that the implanted tumors would not grow, he said. “They were trying to make cancer in mice and unbeknownst to them, something that the veterinarian in the facility had done prevented that,” Prescott said. Shortly after, Prescott said he met Tippens through mutual friends. While director of the Huntsman Cancer Institute in Salt Lake City, Prescott said he “would hear stories all the time about new approaches to cancer medical treatments,” but remained skeptical. However, Prescott said he and a team Tippens is putting together will collaborate to explore alternative care methods. “It would be a wonderful thing if we discovered that there is this compound that has broad activity with dramatic responses like with Mr. Tippens, what a great thing that would be,” he said. Prescott said they plan to spend six to 12 months researching the medical records of cancer patients. In their study, they will consider specifics such as the treatment they received, how they reacted and how long they were given to live. By studying Tippens’ case further, Prescott said they could provide more truth to the dog dewormer medicinal impact. One problem made evident by some anticancer medications is that over time they become ineffective, he said. It is the reason why patients today are seeking other treatments. Most anticancer drugs attack a specific target on or in the cancer cell, he explained. “What often happens is that it works initially and then quits working,” Prescott said. “And the reason is the cancer has continued to change and have additional mutations, so what was the initial targets no longer respond to the drug.” Part of Tippens’ treatment regimen was CBD. Chip Paul, the founder of Owasso-based GnuPharma, a company that specializes in developing natural products, said he is unsure how influential CBD alone was on Tippens’ cancer cells. “If he was just taking cannabidiol, it is doubtful that it affected his cancer because it does not have the right actives in it to be able to signal that,” Paul said. Prescott said as the clinical trial develops, he hopes that it will eventually lead to answers regarding Tippens’ shocking recovery. “I do really applaud Mr. Tippens for his forthrightness and aggressive stance for something he believes has helped him and can help us as a people,” Prescott said. “He has done more than any patient has done in that regard.”

hanniabu 7y ago

Click the "web" link below the link to the story and select another source

echelon 7y ago

This is one of the many viable options US companies have for dealing with EU traffic. GDPR compliance can be extremely expensive to implement, especially for complex software comprised of thousands of microservices that handle customer data. And imagine working in an industry where data retention is legally mandated by other jurisdictions... I'm not saying GDPR is bad (I'm all in favor!), but the costs can be quite large to implement to the letter of the law (GDPR export requirements, etc)

rlpb 7y ago
> GDPR compliance can be extremely expensive to implement... Bullshit. It's trivial to implement. Don't store my personal data. Done. It may be extremely expensive to store and process my personal data and remain GDPR compliant, if you insist on doing that. And admittedly it may be expensive to store and process others' personal data while excluding EU citizens from that mechanism. But the blanket statement "GDPR compliance can be extremely expensive to implement" is on its own extremely misleading in this context. > And imagine working in an industry where data retention is legally mandated by other jurisdictions... Perhaps, but this is not relevant to a news organisation publishing a general article online from the USA, where (AFAIK) there is no such data retention requirement in any jurisdiction within the USA.
- sagebird 7y ago
  It is not trivial for publishers who have years of adding advertising and analytics tools to their website to come up with a strategy for peeling these back or checking compliance. If I had a blog, it would be easy for me to check and decide what to remove or modify. But being part of an organization means that most of the shit on a publisher’s network is a manager’s baby project and is going to require meetings, ego stroking, and if you suggest a change then revenue drops, you will be prime suspect. Not to mention months of managers saying — “well we used to have this really great analytics platform that helped me steer this company but now I can’t do my job because so and so deactivated X”. For many of the tools you might have a contract with a company to provide service. They have people specifically hired to be persuasive calling your leadership to try to keep the relationship going, so they will fight to keep you as a customer. I think the interesting thing is that you can’t pass the buck, you are ultimately responsible for providing compliance, not just choosing tools that claim compliance.

bryanrasmussen 7y ago

As I was trying to find a non gdpr resistant news article I happened to come across this https://www.thesun.co.uk/news/9344028/cocaine-rot-skin-genitals-drug-cut-cattle-dewormer/ https://www.thesun.co.uk/news/9344028/cocaine-rot-skin-genit... "COKE ROT Cocaine can ROT your skin and genitals – as drug is cut with dangerous cattle de-wormer, experts warn" the interesting thing is in the article it says cocaine can be cut with Levamisole, which: was used to treat arthritis and bowel cancer in the past, but it was banned for use by humans in 2000....Now, it's only supposed to be used in veterinary medicine to kill parasitic worms.

cwkoss 7y ago
I wonder if cocaine users have lower incidences of certain kinds of cancers? Would be an interesting thing to look for in large epidemiological studies.

Chris_Chambers 7y ago

How can countries even be accurately detected? IP lookup table? Blindly guessing based on the Accept-Language header?

tass 7y ago

Does this kind of action actually absolve them of GDPR responsibilities? If an EU citizen/resident/etc accessed the site from a country that’s not blocked, or via VPN, are they unable to ask for their information or have it scrubbed? What if a person later becomes an EU citizen? What if they are a dual citizen? I don’t understand how these geo blockers are able to make anyone compliant.

cheald 7y ago
> Does this kind of action actually absolve them of GDPR responsibilities? All the rest of our laws travel with jurisdictions, not with individuals' citizenship status. The GDPR doesn't really have any standing to impose obligations on companies that refuse to do business inside EU jurisdictions. We won't know until it's tested in court, but demonstrating a best effort to keep your product out of EU jurisdiction seems like a pretty good first defense.
- ivolimmen 7y ago
  But if a EU citizen has an account already they are bound to the GDPR. Blocking this account only makes it worse (legally).
  - cheald 7y ago
    The GDPR might assert that they're bound, but an Oklahoma-based business with no business presence or assets inside the EU isn't bound by EU law. This is pretty much the foundation of national sovereignty. How would an EU enforcer actually enforce the GDPR in this case? Unless there's been a violation of a trade agreement, any attempt to apply EU law to a US-based company operating on US soil is going to be utterly impotent.
    - mattlondon 7y ago
      No any company that deals with people in the EU (even non-EU citizens physically in the EU) needs to obey GDPR - simple site explaining it simply here: https://www.compliancejunction.com/countries-subject-gdpr-privacy-law/ https://www.compliancejunction.com/countries-subject-gdpr-pr... Geo location for IPs is a very inexact science so they almost certainly are processing EU citizens' data. Hell I can access it with a VPN while sat in the EU so yep, they are liable if they store anything about me (apparently IP addresses are considered PII in terms of GDPR too) No idea how they'd enforce it - various murky-references to "international law" are floating around. I guess these sort of things are covered in trade treaties etc like with patents and copyright etc.

hrbf 7y ago

I'm pretty sure this is a wrong use of the spirit of HTTP code 451. It is meant for censorship by external forces like governments. If you block people from legislations that don’t allow invasive tracking by default, it’s you doing the censorship, for economic gain no less.